

Press Release January 12, 2010

BIOMEDPARTNERS CLOSES CHF 106 MILLION BIOMEDINVEST II L.P. HEALTHCARE VENTURE FUND AND STRENGTHENS MANAGEMENT TEAM

Basel/Munich – BioMedPartners, one of the leading European healthcare venture capital firms, today announced the closing of BioMedInvest II L.P., its second healthcare venture capital fund, at CHF 106 million. It is further pleased to announce the addition of Dr. Karl Deres as new Venture Partner.

BioMedInvest II L.P. is a healthcare-dedicated fund that invests in private early- to mid-stage companies in Germany, Switzerland and neighbouring European countries. These companies offer significant return potential, as large pharma companies are increasingly acquiring biotech firms to fill their product pipelines. The fund is backed by both existing and new investors, including the two facilities of the European Investment Fund, ERP-EIF and LfA-EIF.

In addition, Dr. Karl Deres will join BioMedPartners as a new Venture Partner and will support the representation office in Munich. Dr. Deres is a biochemist with a strong background in the pharmaceutical industry as well as broad operational expertise and experience in the biotech sector. Dr. Deres worked for more than 15 years for Bayer Schering Pharma and Intervet Schering Plough. In 2007, he founded DPC Pharma Consulting, an advisory company offering services in the pharmaceutical/biotech industry, including interim management in the fields of business & strategic corporate development, clinical & regulatory aspects as well as R&D management.

Founded in 2003, BioMedPartners has become one of the leading European healthcare investors, having raised over CHF 250 million and invested in more than 30 companies until now. Over the last years, BioMedPartners was able to create an excellent track record of successful IPOs and trade sales, including the recent trade sale of ESBATech to Alcon for USD 589 million and the listing of Evolva on the Swiss International Exchange (SIX), and to generate an extraordinary performance by actively engineering exits with a relatively young portfolio.

“The overwhelming support and enthusiasm of existing and new investors validates the excellent and unique investment approach of BioMedPartners. It encourages the management team to continue with its favourable business model by investing in promising early-stage healthcare companies in Europe. BioMedPartners will strive to build a portfolio of mature companies and to generate successful exits and superior return for investors through the active support of companies in their business and corporate development,” commented the management team of BioMedPartners.

About BioMedPartners

BioMedPartners is a leading independent European venture capital firm providing private equity and mezzanine financing to early- to mid-stage healthcare and life sciences companies. Since 2003, BioMedPartners has invested in over 30 highly innovative companies, of which six have already either successfully completed an IPO (Evolva AG, Santhera Pharmaceuticals AG, Arpida AG) or have been acquired by leading pharma companies (ESBATech AG, Glycart Biotechnology AG, Thommen Medical AG). Currently, BioMedPartners manages three funds, BioMedInvest I & II and BioMedCredit Switzerland. With more than CHF 250 million in capital under management and a strong team of experienced specialists and industry experts, as well as an extensive scientific and financial network, BioMedPartners has established itself as one of the leading early-stage healthcare investors in Europe.

For further information, please contact:

Dr. Gerhard Ries, General Partner
BioMedPartners AG
Elisabethenstrasse 23
CH-4051 Basel
Switzerland
T: +41 61 270 3535
F: +41 61 270 3500
E: ries@biomedvc.com
W: www.biomedvc.com

Am Klopferspitz 19/IZB
D-82152 Martinsried
Germany
T: +49 89 550 5475 14
F: +49 89 550 5475 21